CME Stock Analysis — CME Group
Sector: Financials
AI Verdict
CME trades at a steep premium for a financial stock—23.2x forward earnings versus a 14x sector median—so you’re paying up for its regulatory moat, but the numbers say this is expensive for the expected 9.4% growth.
Competitive Moat
CME Group operates the world’s largest derivatives exchange, with network effects from deep liquidity and regulatory barriers that make it nearly impossible for new entrants to replicate. Its dominance in interest rate, equity index, and commodity futures ensures persistent pricing power and high switching costs for institutional clients.
Summary
CME’s exchange monopoly and regulatory moat keep its earnings stable even as trading volumes fluctuate.
Where It Stands
CME has returned 9.07% over the past year, trades at 23.2x next year's earnings (vs. a 14x sector median for financials), and its RSI of 72.2 signals overbought territory.
Key Metrics
- RSI: 72.2 — Overbought
- Trailing P/E: 25.4x
- Forward P/E: 23.2x
- PEG Ratio: 2.83
- Earnings Growth: +0.1%
- Revenue Growth: +0.2%
- Market Cap: $108.3B
- Dividend Yield: 0.02%
- 1-Year Return: 9.07%
- 52-Week High: $329.16
- 52-Week Low: $257.17
Analyst Consensus
10 Buy · 8 Hold · 3 Sell (21 analysts)
Bull Case
Forward EPS is expected to grow 9.4% while trading at 23.2x forward earnings, which is a premium justified only if its exchange dominance keeps profit margins high.
Bear Case
If the P/E reverts to the sector median of 14x, that would mean a 40% valuation drop from current levels, and the 72.2 RSI suggests a near-term pullback risk.
Catalyst to Watch
Watch for regulatory changes or new competitive threats that could erode CME’s exchange exclusivity.